Title of article :
A balancing act in the United States Drug Industry: pioneer and generic drugs, the Orange Book, marketing protection and the US consumer
Keywords :
New drug application , Drug safety , NDA , Grandfather drug , Kefauver-Harris , Drug effectiveness , Generic drug , Pediatric drug , Bioequivalence , Orphan drug , Patent certification , Waxman-Hatch , Pharmaceutical products , Marketing exclusivity , Therapeutic equivalence , Patent protection , Orange Book
